Concepedia

Richard F. Arakaki

RF

39

Publications

5.1K

Citations

22

H-Index

1980

Active since

Affiliations

University of Hawaiʻi at Mānoa(Current)

National Institute of Diabetes and Digestive and Kidney Diseases

George Washington University

University of Hawaii System

Eli Lilly (United States)

Richard F. Arakaki is an author at University of Hawaiʻi at Mānoa specializing in diabetes, medicine, and metabolic syndrome.

Top concepts

Publications per year

1980–2022

39

Publications

39

Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial

Hertzel C. Gerstein, Helen M. Colhoun, Gilles R. Dagenais et al. · The Lancet · 2019 · 2.8K citations · Full text

, , +9

Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial

Hertzel C. Gerstein, Helen M. Colhoun, Gilles R. Dagenais et al. · The Lancet · 2019 · 600 citations · Full text

, , +10

Efficacy and Safety of Dulaglutide Added Onto Pioglitazone and Metformin Versus Exenatide in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-1)

Carol Wysham, Thomas Blevins, Richard F. Arakaki et al. · Diabetes Care · 2014 · 371 citations

Long-term Effects of Metformin on Diabetes Prevention: Identification of Subgroups That Benefited Most in the Diabetes Prevention Program and Diabetes Prevention Program Outcomes Study

David M. Nathan, William C. Knowler, Sharon L. Edelstein et al. · Diabetes Care · 2019 · 121 citations · Full text

A Randomized, Controlled Study of Once-Daily LY2605541, a Novel Long-Acting Basal Insulin, Versus Insulin Glargine in Basal Insulin–Treated Patients With Type 2 Diabetes

Richard M. Bergenstal, Julio Rosenstock, Richard F. Arakaki et al. · Diabetes Care · 2012 · 115 citations · Full text

Rows per page

1–5 of 39